

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 18, No. 4

February 22nd, 2019

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association and membership news*. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- AMA survey on prior authorizations
- CMS coverage of CAR T-cell therapies
- CMS & NGS
- *Multidisciplinary Management of Cancers*
- *2019 Hematologic Malignancies Updates*

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts)

Members. The next regular *ANCO FAX News* will be published on March 8th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

- ☐ Physician Members
- ☐ Nurses & Office Managers
- ☐ Office Staff
- ☐ Colleagues & Representatives

The *Association of Northern California Oncologists* (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge.

The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

More than a quarter of physicians (28%) report that the prior authorization process required by health insurers for certain drugs, tests and treatments have led to serious or life-threatening events for their patients according to a new survey by the *American Medical Association*. Learn more at www.cmadoes.org/newsroom/news/view/ArticleId/27952/Survey-finds-prior-authorization-hurdles-have-led-to-serious-adverse-events.

ANCO and ASCO ask members to contact their Congressional Representatives and urge them to support HR913, the *Clinical Treatment Act*, that would ensure states cover routine care costs of participation in an approved clinical trial for Medicaid enrollees with life-threatening conditions. Routine costs are defined to include non-experimental costs of treating a patient who is participating in a clinical trial such as physician visits or laboratory tests—standard care that would be provided regardless of whether a patient participates in a clinical trial.

CMS has proposed to pay for CAR-T therapies for cancer patients across the country. The proposal specifies that Medicare will cover all FDA-approved CAR-T therapies as long as data is collected about how the patients fare, which could inform the agency's policies about paying for the therapy in the future.

Sixty-three healthcare organizations, including ASCO, ASH, and ACCC, have written CMS expressing serious concerns over the agency's revised interpretation of the National Coverage

Determination (NCD) that may prevent early stage cancer patients with genetic predispositions from accessing next-generation sequencing (NGS). An overarching concern is that, although the NCD was requested for a somatic-based test, the new interpretation will result in Medicare Administrative Contractors (MACs) applying the NCD's terms to both somatic and germline NGS-based testing for patients with cancer. As a result, patient access to medically necessary and relevant testing of germline mutations in patients would be restricted, as would NGS-based testing (both somatic and germline) for Medicare beneficiaries with early-stage cancer. Read the letter at www.accc-cancer.org/docs/documents/advocacy/pdf/group_stakeholder_letter_ngsncd-final-1-31-2019.pdf.

ASCO has been informed that some oncology practices and providers in MIPS have received inaccurate payment adjustments as a result of Medicare Part B drug costs incorrectly being included in the adjustments. CMS is also aware of the error and is working to resolve the issue. ASCO is in contact with CMS and will continue to keep members informed as a solution is implemented. If you believe your adjustment is incorrect for any reason, please contact CMS' QPP help desk at (866) 288-8292; additional questions may be e-mailed to macra@asco.org.

CMS opened the data submission period for MIPS eligible clinicians who participated in Year 2 (2018) of the QPP. Data can be submitted and updated any time up to April 2nd, with two exceptions—CMS Web Interface users need to report their quality performance category data by March 22nd; clinicians who reported quality measures via Medicare Part B claims throughout the 2018 performance year will have their quality data sent to CMS by their MAC. Submit your 2018 MIPS data by visiting the QPP website at qpp.cms.gov/login?. In addition, the **QOPI Reporting Registry, a QCDR brought to you by ASCO and ASTRO, is your one-stop shop for 2019 MIPS reporting.** Visit

practice.asco.org/quality-improvement/quality-programs/qopi-reporting-registry? for more information.

CMA, MOASC, and State Legislative & Regulatory Issues

The *California Oncology Political Action Committee* (or CalCancerPAC), formed by ANCO and MOASC, supports candidates sensitive to the needs of hematologists/oncologists and people living with cancer in California. ANCO membership dues include a contribution to the CalCancerPAC.

With the support of the *National Oncology State Network* (NOSN), ANCO and MOASC are working to create the *California Cancer Caucus*. The goal of the *California Cancer Caucus* is to bring the Capitol community and the oncology community together to improve the access, care, treatment, research, and support for those fighting cancer. The *Caucus* seeks to improve communication and education between cancer care stakeholders and health policy decision makers to improve public policy that has a direct impact on the continuum of care for people living with cancer.

ANCO urges members to contact their State legislators in support of SB38, the *Stop Tobacco Access to Kids Enforcement* (STAKE) *Act* that would prohibit a person from selling or otherwise furnishing tobacco products to a person under 21 years of age and that would prohibit a tobacco retailer from selling, offering for sale, or possessing with the intent to sell or offer for sale a flavored tobacco product.

Effective January 1st, a new California law (AB1753) took effect that requires all security prescription forms to have a uniquely serialized number. The legislation did not include any transition or grandfathering period to allow for continued

use of old controlled substance security prescription forms on or after January 1st. For more information, including answers to frequently asked questions about the implementation of this new law, visit www.mbc.ca.gov/Licensees/Prescribing/AB1753JointStatement.pdf. **CMA is currently working on a legislative fix (AB149) to address this issue immediately to ensure that no patient goes without the essential medicine and care they need.** Contact your state legislators now at actnow.io/yTBt0MN to encourage their support of AB149 that would delay the implementation of AB1753.

Sacramento can be a dangerous place for doctors. Many bills impacting medicine wind their way through the *Capitol* on their journey to the *Governor's* desk. And, many of these bills threaten the medical profession with the backing of powerful lobbyists and PACs. It's critical that **physicians have an advocate at work for them every day and who knows how to speak on their behalf. That advocate is the *California Medical Association* (CMA).** While physicians keep a close eye on their patients, CMA is keeping a close eye on those bills...and more. **Got payment delays? Feeling victimized by payers and overwhelmed by the process? Don't let the health plans mistreat you.** The CMA's *Center for Economic Services* (CES) has a team of reimbursement specialists available to assist ANCO's CMA members experiencing payment problems with third-party payers. In 2018, CMA's CES recovered \$11M from payors on behalf of physician members. For membership, please call (916) 551-2042; for reimbursement assistance, please call CMA's *Reimbursement Helpline* at (888) 401-5911.

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the Jurisdiction E (JE) *Medicare Administrative Contractor* (MAC). Jurisdiction E includes California. Regularly review postings at the

Noridian/JEMAC website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews
Announcements—New Medicare Card: 0 not O; Home Health Compare Refresh; MIPS: Check Your Preliminary 2019 Eligibility; CMS: Beyond the Policy-New Podcast CAR T-cell Therapy: CMS Proposes Coverage with Evidence Development; SNF Provider Preview Reports: Review Your Data by March 4; SNF-PPS Patient Driven Payment Model: Updated Resources; Promoting Interoperability Program: 2019 Resources
Events—Open Payments: Transparency and You Call-March 13; MIPS: 2019 QCDR Measure Development and Review Webinar Series-February 28 and March 5; Home Health Quality Reporting Program In-Person Training-March 5 and 6; SNF Value-Based Purchasing Program: Phase One Review and Corrections Call-March 20
Publications—ICD-10 and Other Coding Revisions to NCDs MLN Matters Article-New; Implementation of the SNF PDPM MLN Matters Article-New; Implementation to Exchange the List of eMDR for Registered Providers MLN Matters Article-New; Medicare Physician Fee Schedule Database: April 2019 Update MLN Matters Article-New; Medicare FFS Response to the 2018 California Wildfires MLN Matters Article-Revised; Advance Beneficiary Notice of Noncoverage Interactive Tutorial-Revised; CLIA Program and Medicare Laboratory Services Fact Sheet-Revised; Medicare Advance Written Notices of Noncoverage Booklet-Revised; Medicare Parts A & B Appeals Process Booklet-Revised; Quality Payment Program: 2017 MIPS Performance Feedback Web-Based Training Course-

New; Appeals Call: Audio Recording and Transcript-New; LCDs MLN Matters Article-Revised; How to Use the Medicare National Correct Coding Initiative Tools Booklet-Revised; How to Use the Medicare Coverage Database Booklet-Revised; Advance Care Planning Fact Sheet-Reminder

- NMP vs IVR Self Service Elements Comparison Tool Available
- Medicare Fee-for-Service (FFS) Response to the 2018 California Wildfires-Revised SE18025
- Implementation to Exchange the List of Electronic Medical Documentation Requests (eMDR) for Registered Providers via the Electronic Submission of Medical Documentation (esMD) System CR11003
- ICD-10 and Other Coding Revisions to NCDs CR11134
- Processing Instructions to Update the Standard Paper Remit (SPR) CR11112
- MLN Connects-February 7, 2019
- MolDX: BRCA1 and BRCA2 Genetic Testing LCD-R3
- MolDX: Molecular Diagnostic Tests (MDT) LCD-R9
- Quarterly Update to the Medicare Physician Fee Schedule Database (MPFSDB)-April 2019 Update CR11163
- New Medicare Card: Are You Using the MBI?
- Local Coverage Determinations (LCDs)-Revised CR10901
- Lab: Flow Cytometry LCD-R12
- Chemotherapy Administration-R17 and R18
- Lab: Bladder/Urothelial Tumor Markers LCD-R2

- Appeals Submission and Status Inquiry-NMP Tutorial Available

Forthcoming *Noridian/JEMAC*

meetings/webinars/workshops include:

- Home Health Referrals and Clinical Documentation Requirements Webinar (February 26)
- Submitting Your Enrollment Online-Part 1 Webinar (I&A; February 27)
- Modifier 59, National Correct Coding Initiative (NCCI) and Medically Unlikely Edits (MUE) Webinar (February 28)
- Mammography, Pap and Pelvic Screenings-After Hours Webinar (February 28)
- What To Do With Rejections for Overlapping Claims Webinar (March 7)
- PECOS Part 1: Full Overview of PECOS Webinar (March 13)
- Telehealth Services Webinar (March 19)
- Telehealth Services-After Hours Webinar (March 21)
- PECOS Part 2: Full Overview of PECOS Webinar (March 27)
- Independent Diagnostic Testing Facility (IDTF) Enrollment Webinar (April 10)
- Medicare Part A/B Revalidation Webinar (April 24)
- Submitting Your Enrollment Online-Part 1 Webinar (I&A; May 29)
- Submitting Your Enrollment Online-Part 2 Webinar (PECOS; June 26)

Visit med.noridianmedicare.com/web/jeb/education/training-events for more information and to register.

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

19th Multidisciplinary Management of Cancers: A Case-based Approach

The 19th *Multidisciplinary Management of Cancers: A Case-based Approach* returns to the *Silverado Resort and Spa* in Napa on March 15-17th. The meeting is sponsored by the *Association of Northern California Oncologists*, *Stanford Cancer Institute*, *UC Davis Comprehensive Cancer Center*, and the *UCSF Helen Diller Family Comprehensive Cancer Center*. The meeting announcement was mailed in mid-November; learn more, register, and arrange for housing at www.multicancers.org

SAVE THE DATES ANCO's 2019 Hematologic Malignancies Updates

ANCO is organizing a series of *Hematologic Malignancies Updates* in 2019 on May 18th in Palo Alto, September 14th in Sacramento, and November 16th in San Francisco. These updates are supported by *AstraZeneca*, *Celgene*, *Janssen Oncology*, *Pharmacyclics*, and *Takeda Oncology*. Watch for the first meeting announcement in late March.

Additional Education Meetings

February 28th-March 2nd

ASCO-SITC Clinical Immuno-Oncology Symposium

ASCO & Society for Immunotherapy of Cancer
San Francisco
(<http://immunosym.org>)

March 5th

Medical Update on Ovarian Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 7th

Update on Chronic Lymphocytic Leukemia (CLL)

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 14-16

The Multidisciplinary Thoracic Cancers
Symposium
ASCO, ASTRO, & The Society of Thoracic
Surgeons
San Diego
(<http://thoracicsymposium.org>)

March 15th

Upcoming Trends in Renal Cell Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 18th

Advances in the Treatment of Colorectal Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 19th

Caregiving to Your Loved One with Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 20th

*Triple Negative Breast Cancer and African
American Women*
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 20th-22nd

*45th Annual Meeting & Cancer Center Business
Summit*
ACCC
Washington, D.C.
(<https://www.accc-cancer.org/home/attend/accc-45th-annual-meeting-cancer-center-business-summit?>)

March 21st

*Update on Chronic Lymphocytic Leukemia (CLL)
from the 2018 ASH Annual Meeting*
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

April 3rd

*Taking Your Pills on Schedule: Its Importance in
Treating Cancer*

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

April 4-5th

2019 Community Oncology Conference
Community Oncology Alliance
Lake Buena Vista FL
(www.coaconference.com)

April 8th

*Joys and Challenges of Pets in Your Home When
You Have Cancer*

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

April 8-9th

11th Annual Palliative Care Summit
Coalition for Compassionate Care of California
& Children's Hospice Palliative Care Coalition
San Francisco
(cccssummit.org)

April 10th

*Progress in the Treatment of Waldenstrom's
Macroglobulinemia (WM)*
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

April 15th

*Managing Eye and Vision Changes Related to
Cancer Treatments*
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

Please contact the ANCO office for more
information about these meetings.

| |
|---|
| <p>ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS [Editor's Note: All ANCO members are also eligible for several tangible benefits.]</p> |
|---|

Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of**

Directors teleconference is scheduled for February 27th. Please call José Luis González, ANCO Executive Director, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

A current **Directory of Members** is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO Board believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi-Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Annadel Medical Group/St Joseph's Heritage Healthcare, Diablo Valley Oncology & Hematology Medical Group, EPIC Care, Marin Cancer Care, Pacific Cancer Care, and Palo Alto Medical Foundation* for their multi-site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*

- *University of California, San Francisco*

UC San Francisco will host the **5th World Congress on Controversies in Breast Cancer (CoBrCA): When is Less More?** on September 4-6th. For additional information, please visit cobrca.org. ANCO members may use discount code *cobrca10* to receive a 10% discount on registration.

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Adaptive Biotechnologies
Agiros Pharmaceuticals
Alexion Pharmaceuticals • AMGEN
AMAG Pharmaceuticals • Array BioPharma
Astellas Oncology • AstraZeneca
Bayer Healthcare Pharmaceuticals
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Celgene • Clovis Oncology • Coherus Biosciences
Daiichi Sankyo • Eisai • EMD Serono • Exelixis
Foundation Medicine • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Janssen Oncology • Jazz Pharmaceuticals
Kite Pharmaceuticals • Lexicon Pharmaceuticals
Lilly Oncology • Merck
Novartis Oncology • Pfizer Oncology
Pfizer US Biosimilars • Pharmacyclics
Puma Biotechnology • Sandoz Biopharmaceuticals
Sanofi Genzyme • Seattle Genetics
Stemline Therapeutics • Taiho Oncology
Takeda Oncology • Tempus Labs
TerSera Therapeutics • Tesaro
Teva Oncology • Verastem Oncology*

We especially wish to thank and welcome *Adaptive Biotechnologies, Heron Therapeutics, Stemline Therapeutics, Tempus Labs, and Verastem Oncology* as new Corporate Members for 2019.

Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**.

ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

Janssen Oncology informs ANCO that the *United States Food and Drug Administration* has approved a split-dosing regimen of Darzalex for patients with multiple myeloma, providing physicians the option to split the first infusion of the CD38-directed monoclonal antibody over two consecutive days or complete in a single session.

Merck informs ANCO that the *United States Food and Drug Administration* has approved Keytruda for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Sanofi Genzyme informs ANCO that the *United States Food and Drug Administration* has approved Cablivi for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Stemline Therapeutics informs ANCO that the *United States Food and Drug Administration* has approved Elzonris for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Publications, Resources, Services, & Surveys

ASCO is inviting all oncology practices to participate in the 2019 *Survey of Oncology Practice Operations* which aims to give practices a deeper look at a variety of oncology management topics, including productivity, revenue, staffing levels, salaries, expenses, and more. The *Survey* is open through Friday, March 8th. Respondents who complete the *Survey* will receive entry into drawing for a free year of Practice Administrator or other Affiliated Health Professional ASCO membership; a comprehensive report highlighting how your

practice compares to others; salary statistics on 30 oncology staff roles; and, a full data set of deidentified data. Learn more and take the *Survey* at www.asco.org/advocacy-policy/asco-in-action/learn-how-your-practice-compares-take-ascos-2019-survey-practice?.

ASCO seeks applications for research grants for projects that use data from CancerLinQ Discovery, an offering of ASCO's CancerLinQ initiative, as a source. CancerLinQ Discover provides curated sets of de-identified data from cancer patients to academic researchers, government agencies, and others in the oncology community to generate practical knowledge that will improve care. With grants of \$32,500 each, ASCO will provide early and mid-career clinical oncology and health service investigators with real-world evidence that can inform their research. Research topics may include—but are not limited to—adoption of treatment guidelines across the U.S.; development of quality measures with the highest impact for clinical care; measuring the impact of educational programs on clinical practices; supportive evidence for informing ASCO policy priorities; or novel research on other topics. The deadline for submitting a research proposal is April 30th. For more information, visit www.conquer.org/cancerlinq-discovery-research-support-grant.

The ASCO Guidelines App is your go-to tool for implementing guideline recommendations into practice. This user-friendly App provides health care providers, patients, and caregivers with the recommended cancer care options for a variety of cancer types. It also includes interactive tools to inform treatment decisions at the point of care, thus increasing the quality of care provided to patients. The App is free to members and nonmembers, kept up to date, and will continue to grow as more guidelines and tools are added. Download the App at www.asco.org/guidelines or www.asco.org/apps.

ASCO's Clinical Affairs Department provides services, education, and resources to support

oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/practice-guidelines/practice-support.

ASCO's Practice Consulting Services & Support offers personalized services to help practices achieve operational goals. Their team of nationally recognized consultants in oncology practice management is dedicated to assisting practices succeed in today's constantly evolving practice environment. Services include readiness assessment, practice operational assessment, practice transformation implementation support, analytical services, triage pathways. For more information, visit practice.asco.org.

ASCO's Practice Engagement Program helps administrators, physicians, and other members of the care team navigate ASCO tools, programs, and resources available to help oncology practices respond to the changes occurring in the cancer care delivery system.

ASCO's Practice Central is a website that serves as an online information hub to help oncology professionals navigate a complicated and ever-changing practice environment—while providing high-quality patient care. ASCO *Practice Central* offers oncology practices easy-to-access information, tools, and resources that are designed to foster effective business practices and support high-quality patient care. Bookmark ASCO *Practice Central* at practice.asco.org.

Improve your business operations with ASCO's PracticeNET, a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. Learn more at practice.asco.org/practice-support/practice-benchmarking/practicenet.

Data abstraction for ASCO's QOPI Round 1 will close on June 3rd. Round 1 final reports will be available approximately two weeks after the round closes. Learn more at practice.asco.org/quality-improvement/quality-programs/quality-oncology-practice-initiative?.

ASCO offers the QOPI Certification Program to recognize QOPI participants who achieve rigorous standards for cancer care. The *QOPI Certification* designation can be used by certified practices to demonstrate an advanced commitment to quality. *The Doctors Company*, the nation's largest physician-owned medical malpractice insurer, offers up to a 10% premium discount to physicians whose practices have achieved QOPI certification. Learn more at www.thedoctors.com/qcp.

ASCO's 2019 Self-Evaluation App: Breast and Gynecologic Cancers, formerly known as the ASCO MOC App, features six courses, with 20-questions each, on a variety of topics in Breast and Gynecologic Cancers. Test your knowledge and confidence with these multiple-choice questions, which include patient case information, educational links, and answer rationales. Available via the Android and Apple app; learn more at shop.asco.org/sacjan19_2019-self-evaluation-app-breast-and-gynecologic-cancers/.

Managing the cost of cancer care can be overwhelming and ASCO Answers can help your patients. *ASCO Answers* gives your patients practical guidelines for managing the cost of their cancer care. It covers health insurance benefits, information about the *Affordable Care Act*, tips, resources, & more! Learn more and order *ASCO Answers* at shop.asco.org/mccc15_managing-the-cost-of-cancer-care-pack-of-50-booklets/?.

ACCC's 2019 Patient Assistance and Reimbursement Guide is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-

pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. Visit www.accc-cancer.org/home/learn/publications/patient-assistance-and-reimbursement-guide to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* (FAN) app is available at accc-fan-app.org.

NCCN has published and/or updated their *Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Evidence Blocks, Guidelines for Patients, Imaging Appropriate Use Criteria, and/or Radiation Therapy Compendium* for: AIDS-related Kaposi Sarcoma (V2.2019), B-cell lymphomas (V1.2019), bladder cancer (V1.2019), breast cancer (V4.2018), distress management (V1.2019), malignant pleural mesothelioma (V1.2019), non-small cell lung cancer (V3.2019), palliative care (V2.2019), soft-tissue sarcoma (V2.2019), testicular cancer (V1.2019), thymomas and thymic carcinomas (V1.2019), uterine neoplasms (V3.2019). Go to www.nccn.org for more information.

The *Academy of Oncology Nurse & Patient Navigators* (AONN+) is pleased to share that the application period for the certification exam being held at the AONN+ Midyear Conference is now open through April 26th. Learn more at aonnonline.org/certification.

Individual Membership Dues for 2019

Membership renewal notices for 2019 were mailed to all members the last week in November. Second notices of membership renewal for 2018 were mailed to all members in early February. If you have not yet done so, then please return your 2019 membership dues to ANCO now to ensure your inclusion in *The ANCO Directory of Members*. Be sure to provide ANCO with your e-mail address and the name(s) and e-mail address(es) of office and/or nurse

manager contact(s). Those not renewing their membership by June 30th will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits. Contact the ANCO office if you do not receive or misplaced your membership dues renewal notice.

ANCO seeks new members. **All members of a practice should join ANCO. And, ANCO seeks to enroll radiation oncologists as members**, so please send us contact information for the radiation oncologists within your practice and/or to whom you refer patients.

Remember, a larger ANCO is a stronger ANCO!